Altered Gut Microbiome in Patients With DermatomyositisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
The study examined the gut microbiome of patients with dermatomyositis (DM), an autoimmune muscle disease, compared with healthy controls. Researchers used 16S ribosomal RNA gene sequencing on fecal samples to compare microbial composition and diversity between the two groups. They also tested whether microbial differences tracked with DM-specific clinical features, including myositis-specific autoantibodies (MSAs), and performed predicted metagenomic functional analysis. Dietary intake was assessed with a 24-hour recall to account for its influence on the microbiome.
Who was studied?
The cohort consisted of 36 patients with dermatomyositis and 26 healthy controls, whose fecal samples underwent 16S sequencing. Within the DM group, a subset of 12 patients had interstitial lung disease (ILD)-associated myositis-specific autoantibodies, specifically antisynthetase antibodies or anti-melanoma differentiation-associated protein 5 antibodies. This subgroup was analyzed separately for microbial composition and diversity differences.
What were the most important findings?
Patients with dermatomyositis trended toward lower overall microbial diversity compared with healthy controls. A higher physician global damage score, a measure of cumulative disease-related damage, was significantly correlated with lower microbial diversity in DM patients. Patients with ILD-associated myositis-specific autoantibodies (antisynthetase or anti-MDA5 antibodies) showed significant differences in microbial composition and further reductions in microbial diversity compared with other DM patients.
What are the greatest implications of this study?
These findings suggest that gut microbial alterations in dermatomyositis are not uniform but relate to specific clinical subtypes and disease severity. The association between lower diversity and higher damage scores raises the possibility that gut dysbiosis tracks with, or contributes to, cumulative organ damage in DM. The distinct microbial signature in patients with ILD-associated autoantibodies suggests the gut microbiome could eventually help characterize or stratify DM patients by autoantibody-defined subgroups, though this abstract alone does not establish causation.